IgE receptor antagonists
US7101851B2 · kind B2 · utility
2Cited by
7References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 26, 2001 |
| Grant date | Sep 5, 2006 |
| Priority date | — |
| Expiry date | Apr 13, 2022 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2500/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides novel compounds which bind to the high affinity receptor for immunoglobulin E (IgE) designated FcεRI and methods for identifying and preparing such compounds. In particular aspects, the invention provides to the treatment of disorders mediated by IgE utilizing the novel compounds of the invention. The invention also provides composition, such as pharmaceutical compositions, comprising the novel compounds, as well as for their use in research, diagnostic, therapeutic, and prophylactic methods.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.